MCID: SMT006
MIFTS: 50

Somatoform Disorder malady

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Somatoform Disorder

Aliases & Descriptions for Somatoform Disorder:

Name: Somatoform Disorder 12 14 69
Physiological Malfunction Arising from Mental Factor 12
Psychophysiologic Disorders 69
Psychosomatic Disorder 12

Classifications:



Summaries for Somatoform Disorder

Disease Ontology : 12 A disease of mental health that involves physical symptoms suggesting a physical illness where the biological or medical cause of the symptoms is indeterminate.

MalaCards based summary : Somatoform Disorder, also known as physiological malfunction arising from mental factor, is related to personality disorder and somatization disorder, and has symptoms including dyspnea, headache and meningism. An important gene associated with Somatoform Disorder is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Th17 cell differentiation. The drugs Pregabalin and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Somatoform Disorder

Diseases related to Somatoform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Related Disease Score Top Affiliating Genes
1 personality disorder 30.1 COMT OPRM1 TAC1 TRPV1
2 somatization disorder 11.8
3 hypochondriasis 11.3
4 conversion disorder 11.1
5 dissociative seizures 11.1
6 psychogenic movement 11.1
7 body dysmorphic disorder 11.1
8 pain disorder 11.1
9 anxiety disorder 10.5
10 panic disorder 10.5
11 obsessive-compulsive disorder 10.4
12 toxic optic neuropathy 10.3 IL1A IL1B
13 asymptomatic neurosyphilis 10.2 IL2RA IL4
14 ileocolitis 10.2 IL1B IL4
15 autoimmune progesterone dermatitis 10.2 FAAH TRPV1
16 alexithymia 10.2
17 nasopharyngitis 10.2 IL1A IL1B IL4
18 gonococcal endophthalmia 10.2 IL1B IL1RN IL4
19 parasitic protozoa infectious disease 10.2 IL1A IL1B IL4
20 c8 deficiency, type ii 10.2 COMT FAAH OPRM1
21 mental retardation hypotonia skin hyperpigmentation 10.2 IL1A IL1B IL1RN
22 peripheral vertigo 10.2 COMT OPRM1
23 glossitis 10.2 IL1A IL1B IL1RN
24 skin conditions 10.2 IL1A IL1B IL1RN
25 childhood endodermal sinus tumor 10.1 IL1B TAC1 TRPV1
26 basal cell carcinoma 3 10.1 COMT OPRM1 TPH1
27 classic type lipoma 10.1 IL1A IL1B IL1RN
28 deafness, autosomal recessive 20 10.1 TAC1 TPH1 TRPV1
29 tuberculous peritonitis 10.1 TAC1 TPH1 TRPV1
30 erythematosquamous dermatosis 10.1 IL1A IL1B IL4
31 eyelid neoplasm 10.1 IL4 TAC1 TRPV1
32 acquired polycythemia 10.1 IL4 TAC1 TRPV1
33 simultanagnosia 10.1 OPRM1 TAC1 TRPV1
34 myiasis 10.1 IL1RN IL2RA IL4
35 childhood choriocarcinoma of the testis 10.1 IL1A IL2RA IL4
36 cervical carcinosarcoma 10.1 OPRM1 TAC1 TRPV1
37 band keratopathy 10.1 IL1A IL1B OPRM1
38 nervous system cancer 10.1 IL1A IL1B IL4
39 uterine ligament clear cell adenocarcinoma 10.1 IL1B TAC1 TRPV1
40 spontaneous ocular nystagmus 10.1 IL1B IL4 TAC1
41 urea cycle disorder 10.1 COMT IL1B NGF
42 periodontosis 10.1 IL1A IL1RN IL2RA
43 esophageal candidiasis 10.1 IL1A IL2RA IL4
44 autosomal recessive type iv ehlers-danlos syndrome 10.1 IL1A IL1B IL1RN IL4
45 bare lymphocyte syndrome, type i 10.1 IL1A IL1B IL1RN IL4
46 bone angioendothelial sarcoma 10.1 IL1A IL1B IL1RN IL4
47 acute chest syndrome 10.0 IL1B IL4 TAC1
48 malignant renovascular hypertension 10.0 NGF TAC1
49 borderline personality disorder 10.0
50 autism spectrum disorder 10.0 COMT OPRM1 TAC1 TRPV1

Graphical network of the top 20 diseases related to Somatoform Disorder:



Diseases related to Somatoform Disorder

Symptoms & Phenotypes for Somatoform Disorder

UMLS symptoms related to Somatoform Disorder:


dyspnea, headache, meningism, pain, paresis, reflex, abnormal, seizures, vertigo, multiple somatic complaints, neurobehavioral manifestations, labored breathing, neuromuscular manifestations, symptoms

MGI Mouse Phenotypes related to Somatoform Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 OPRM1 TPH1 TRPA1 TRPV1 COMT FAAH
2 behavior/neurological MP:0005386 10.02 COMT FAAH NGF OPRM1 SCN9A TAC1
3 cardiovascular system MP:0005385 9.92 COMT IL1A IL1B TPH1 TRPV1 IL1RN
4 immune system MP:0005387 9.9 CABIN1 COMT IL1A IL1B IL1RN IL2RA
5 integument MP:0010771 9.73 IL1B IL1RN IL4 NGF OPRM1 SCN9A
6 nervous system MP:0003631 9.28 COMT FAAH IL1B IL4 NGF OPRM1

Drugs & Therapeutics for Somatoform Disorder

Drugs for Somatoform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
3
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
4
Propranolol Approved, Investigational Phase 4 525-66-6 4946
5
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 401 6234
6
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
7
Zolpidem Approved Phase 4,Phase 3 82626-48-0 5732
8 Piracetam Approved Phase 4,Phase 3 7491-74-9
9
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 54910-89-3 3386
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
13
Sertraline Approved Phase 4,Phase 3 79617-96-2 68617
14
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
15
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-84-3 187
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
17
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
18
Tibolone Approved Phase 4 5630-53-5
19
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
20
Flunarizine Approved Phase 4 52468-60-7 941361
21
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
22
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
23
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
24
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
25
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
26
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
27 Anticoagulants Phase 4,Phase 2
28 Pentosan Sulfuric Polyester Phase 4
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormone Antagonists Phase 4,Phase 2
31 Hormones Phase 4,Phase 2
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
33 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
34 Anticonvulsants Phase 4,Phase 3,Phase 2
35 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 1,Phase 2
37 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
38 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
39
Serotonin Phase 4,Phase 3,Phase 1,Phase 2 50-67-9 5202
40 Serotonin Agents Phase 4,Phase 3,Phase 1,Phase 2
41 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
42 Anesthetics Phase 4,Phase 3,Phase 2
43 Anesthetics, Local Phase 4,Phase 3,Phase 2
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Anxiety Agents Phase 4,Phase 3
47 Antiparkinson Agents Phase 4,Phase 3
48 calcium channel blockers Phase 4,Phase 3
49 Calcium, Dietary Phase 4,Phase 3,Phase 2
50 Tranquilizing Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 236)
id Name Status NCT ID Phase
1 Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome Unknown status NCT01895153 Phase 4
2 A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol Completed NCT00709735 Phase 4
3 Effect of Propranolol on Preventing Posttraumatic Stress Disorder Completed NCT00158262 Phase 4
4 Developing Memory Reconsolidation Blockers as Novel Post-traumatic Stress Disorder (PTSD) Treatments Completed NCT01490697 Phase 4
5 Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing Completed NCT00156533 Phase 4
6 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4
7 Fluoxetine in Pediatric Body Dysmorphic Disorder Completed NCT00245635 Phase 4
8 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4
9 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4
10 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Completed NCT01250184 Phase 4
11 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4
12 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4
13 The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder Recruiting NCT01822288 Phase 4
14 GRASSP: Gralise® for Spine Surgery Pain Recruiting NCT01764464 Phase 4
15 Neurologic Signatures of Chronic Pain Disorders Recruiting NCT02747940 Phase 4
16 Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders Recruiting NCT03036293 Phase 4
17 Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic Active, not recruiting NCT02007928 Phase 4
18 CBT as an Adjunct to SRIs in the Treatment of BDD Terminated NCT00211809 Phase 4
19 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4
20 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Terminated NCT01879930 Phase 4
21 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4
22 Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study Terminated NCT01280747 Phase 4
23 Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome Terminated NCT00780390 Phase 4
24 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4
25 Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome Withdrawn NCT00673972 Phase 4
26 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
27 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
28 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
29 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3
30 Psychological Prevention of Internalizing Disorders Unknown status NCT00564239 Phase 3
31 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic Completed NCT01091662 Phase 3
32 Eslicarbazepine Acetate Monotherapy Long Term Study Completed NCT00910247 Phase 3
33 DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms Completed NCT00130988 Phase 3
34 Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Completed NCT00050583 Phase 3
35 Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Completed NCT01119469 Phase 3
36 Integrated Treatment Program for Hypochondriasis in Primary Care Settings Completed NCT00368212 Phase 3
37 Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Completed NCT00149799 Phase 3
38 Treatment of Patients With Longstanding Unexplained Health Complaints Completed NCT00132197 Phase 2, Phase 3
39 Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus Completed NCT00381771 Phase 2, Phase 3
40 Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
41 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders Completed NCT00769561 Phase 2, Phase 3
42 A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. Completed NCT00246142 Phase 3
43 Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) Completed NCT00817128 Phase 2, Phase 3
44 A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1 Completed NCT00166452 Phase 3
45 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3
46 A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome Completed NCT01008553 Phase 3
47 Pharmacovigilance in Gerontopsychiatric Patients Recruiting NCT02374567 Phase 3
48 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Recruiting NCT02858453 Phase 3
49 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Recruiting NCT02390505 Phase 3
50 Treatment of Globus Sensations With Psychotherapy Active, not recruiting NCT01590992 Phase 2, Phase 3

Search NIH Clinical Center for Somatoform Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Somatoform Disorder

Anatomical Context for Somatoform Disorder

MalaCards organs/tissues related to Somatoform Disorder:

39
Brain

Publications for Somatoform Disorder

Articles related to Somatoform Disorder:

(show top 50) (show all 101)
id Title Authors Year
1
Dysaesthetic penoscrotodynia may be a somatoform disorder: results from a two-centre retrospective case series. ( 26932754 )
2016
2
Suicidality in patients with somatoform disorder - the speechless expression of anger? ( 27821358 )
2016
3
The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders. ( 26785798 )
2016
4
Somatic symptom disorder and undifferentiated somatoform disorder, which is broader? Response to "Clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS)". ( 27542553 )
2016
5
Harm avoidance and persistence are associated with somatoform disorder psychopathology: A study in Taiwan. ( 26919056 )
2016
6
Depression and anxiety among patients with somatoform disorders, panic disorder, and other depressive/anxiety disorders in Taiwan. ( 27179181 )
2016
7
Cognitive Alexithymia Mediates the Association Between Avoidant Attachment and Interpersonal Problems in Patients With Somatoform Disorder. ( 27185015 )
2016
8
The day-to-day concurrence of bodily complaints and affect in patients with severe somatoform disorder. ( 26032264 )
2015
9
Insecure attachment strategies are associated with cognitive alexithymia in patients with severe somatoform disorder. ( 26060261 )
2015
10
Intensive multidisciplinary treatment of severe somatoform disorder: a prospective evaluation. ( 25594786 )
2015
11
Relationship between alexithymia and coping strategies in patients with somatoform disorder. ( 24403835 )
2014
12
The spiral aftereffect technique (SAT) can differentiate between depressive and somatoform disorder patients. ( 24897884 )
2014
13
Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. ( 24525655 )
2014
14
A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? ( 25388965 )
2014
15
Is the DSM-5 chapter on somatic symptom disorder any better than DSM-IV somatoform disorder? ( 25029686 )
2014
16
Fibromyalgia syndrome: a somatoform disorder? ( 24453056 )
2014
17
Psychotherapy for severe somatoform disorder: problems with missing studies. ( 24590981 )
2014
18
Effectiveness of psychotherapy for severe somatoform disorder: meta-analysis. ( 24385460 )
2014
19
Explanatory models of somatoform disorder patients attending a psychiatry outpatient clinic: A study from North India. ( 24029246 )
2013
20
Changes in brain activity of somatoform disorder patients during emotional empathy after multimodal psychodynamic psychotherapy. ( 23966922 )
2013
21
Somatoform disorders in patients with chronic pain. ( 24288382 )
2013
22
Cognitive and affective dimensions of difficulties in emotional functioning in somatoform disorders and borderline personality disorder. ( 23006331 )
2013
23
Prevalence, demographic and clinical characteristics of body dysmorphic disorder among psychiatric outpatients with mood, anxiety or somatoform disorders. ( 22029732 )
2012
24
Altered brain activity during emotional empathy in somatoform disorder. ( 21998038 )
2012
25
Public familiarity with the terms somatoform disorder and functional disorder in Germany: results from a representative population survey. ( 22690365 )
2012
26
Effect of tryptophan hydroxylase gene polymorphism on aggression in major depressive disorder and undifferentiated somatoform disorder. ( 22697203 )
2012
27
Gabapentin as add-on treatment for somatoform disorder: a case report. ( 22240859 )
2012
28
Presentation of the Multidisciplinary Guideline Medically Unexplained Physical Symptoms (MUPS) and Somatoform Disorder in the Netherlands: disease management according to risk profiles. ( 22281461 )
2012
29
Somatoform disorder and the DSM-V Workgroup's interim proposals: two central issues. ( 22664310 )
2012
30
Rethinking the Psychogenic Model of Complex Regional Pain Syndrome: Somatoform Disorders and Complex Regional Pain Syndrome. ( 24223338 )
2012
31
Validation of the PHQ-15 for somatoform disorder in the occupational health care setting. ( 21785907 )
2012
32
Relationship between neural activity and immunity in patients with undifferentiated somatoform disorder. ( 22801462 )
2012
33
Definition and structure of body-relatedness from the perspective of patients with severe somatoform disorder and their therapists. ( 22905144 )
2012
34
Dysfunctional affect regulation in borderline personality disorder and in somatoform disorder. ( 22984638 )
2012
35
Hypochondriasis, somatoform disorders, and anxiety disorders: sociodemographic variables, general psychopathology, and naturalistic treatment effects. ( 22551794 )
2012
36
Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. ( 22367417 )
2012
37
Serotonin-related gene pathways associated with undifferentiated somatoform disorder. ( 21531467 )
2011
38
Course and prediction of somatoform disorder and medically unexplained symptoms in primary care. ( 21762827 )
2011
39
Somatoform disorder after conscious sedation. ( 22136794 )
2011
40
Association of somatoform disorder symptoms with genetic variants potentially involved in the modulation of nociception. ( 21037510 )
2011
41
Multimodal psychodynamic psychotherapy induces normalization of reward related activity in somatoform disorder. ( 21198419 )
2011
42
Childhood traumatization by primary caretaker and affect dysregulation in patients with borderline personality disorder and somatoform disorder. ( 22893813 )
2011
43
A suspected case of somatoform disorder successfully treated with an herbal medicine. ( 21299430 )
2011
44
Affect dysregulation in borderline personality disorder and somatoform disorder: differentiating under- and over-regulation. ( 20545496 )
2010
45
The concept of comorbidity in somatoform disorder--a DSM-V alternative for the DSM-IV classification of somatoform disorder. ( 20004307 )
2010
46
Causal symptom attributions in somatoform disorder and chronic pain. ( 20004296 )
2010
47
Acoustic neuroma identified after electroconvulsive therapy in a patient with recurrent major depression and undifferentiated somatoform disorder. ( 20357670 )
2010
48
Towards positive diagnostic criteria: a systematic review of somatoform disorder diagnoses and suggestions for future classification. ( 20403499 )
2010
49
Affect dysregulation and dissociation in borderline personality disorder and somatoform disorder: differentiating inhibitory and excitatory experiencing states. ( 20938867 )
2010
50
Shared neural activity in panic disorder and undifferentiated somatoform disorder compared with healthy controls. ( 20673555 )
2010

Variations for Somatoform Disorder

Expression for Somatoform Disorder

Search GEO for disease gene expression data for Somatoform Disorder.

Pathways for Somatoform Disorder

Pathways related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 IL1B NGF OPRM1 TRPA1 TRPV1
2
Show member pathways
12.4 IL1A IL1B IL2RA IL4
3 12.31 COMT NGF OPRM1 SCN9A TPH1
4 12.26 CABIN1 IL1B IL1RN IL2RA IL4
5
Show member pathways
12.22 IL1A IL1B IL4 OPRM1
6
Show member pathways
11.96 IL1A IL1B IL4
7
Show member pathways
11.84 IL1A IL1B IL2RA
8 11.8 IL1A IL1B IL4
9
Show member pathways
11.77 IL1B IL2RA IL4
10 11.61 IL1A IL1B IL4 OPRM1
11 11.57 IL1B IL2RA IL4
12
Show member pathways
11.51 CABIN1 IL2RA IL4
13 11.44 IL1A IL1B IL2RA IL4
14 11.31 IL1A IL1B IL1RN NGF TAC1 TPH1
15 10.97 IL1A IL1B IL4
16 10.95 IL1A IL1B IL1RN IL4
17
Show member pathways
10.93 COMT TPH1
18 10.7 IL1B IL4
19 10.28 IL1A IL1B

GO Terms for Somatoform Disorder

Biological processes related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 IL1A IL1B IL1RN IL2RA IL4
2 cell surface receptor signaling pathway GO:0007166 9.84 CABIN1 IL2RA TRPA1 TRPV1
3 inflammatory response GO:0006954 9.8 IL1A IL1B IL1RN IL2RA SCN9A TAC1
4 calcium ion transmembrane transport GO:0070588 9.77 OPRM1 TRPA1 TRPV1
5 response to organic cyclic compound GO:0014070 9.76 COMT IL4 TRPA1
6 response to lipopolysaccharide GO:0032496 9.72 COMT GCH1 IL1B OPRM1 TAC1
7 positive regulation of T cell proliferation GO:0042102 9.63 IL1B IL2RA IL4
8 positive regulation of T cell differentiation GO:0045582 9.58 IL2RA IL4
9 microglial cell activation GO:0001774 9.57 IL4 TRPV1
10 behavioral response to pain GO:0048266 9.56 SCN9A TRPV1
11 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 IL1A IL1B
12 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.54 IL1A IL1B IL4
13 positive regulation of chemokine biosynthetic process GO:0045080 9.52 IL1B IL4
14 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.49 IL1A IL1B
15 ectopic germ cell programmed cell death GO:0035234 9.48 IL1A IL1B
16 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.43 TRPA1 TRPV1
17 thermoception GO:0050955 9.4 TRPA1 TRPV1
18 sensory perception of pain GO:0019233 9.35 OPRM1 SCN9A TAC1 TRPA1 TRPV1
19 fever generation GO:0001660 9.33 IL1A IL1B TRPV1
20 response to pain GO:0048265 9.02 COMT GCH1 TAC1 TRPA1 TRPV1

Molecular functions related to Somatoform Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL1A IL1B IL1RN IL4
2 calcium-release channel activity GO:0015278 9.16 TRPA1 TRPV1
3 interleukin-1 receptor binding GO:0005149 8.8 IL1A IL1B IL1RN

Sources for Somatoform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....